The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Aug. 16, 2023
Applicants:
Gilead Sciences, Inc., Foster City, CA (US);
Carna Biosciences, Inc., Kobe, JP;
Inventors:
Masaaki Sawa, Kobe, JP;
Mai Arai, Kobe, JP;
Ryoko Nakai, Kobe, JP;
Hirokazu Matsumoto, Kobe, JP;
Jonathan William Medley, San Bruno, CA (US);
Leena Patel, Seattle, WA (US);
Qingming Zhu, Walnut Creek, CA (US);
Tetsuya Kobayashi, Pleasanton, CA (US);
Assignees:
Gilead Sciences, Inc., Foster City, CA (US);
Carna Biosciences, Inc., Kobe, JP;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/395 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/538 (2006.01); A61K 31/55 (2006.01); A61K 31/553 (2006.01); A61K 31/695 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07D 519/00 (2006.01); C07F 7/18 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/538 (2013.01); A61K 31/55 (2013.01); A61K 31/553 (2013.01); A61K 31/5545 (2017.08); A61K 31/695 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07D 519/00 (2013.01); C07F 7/1804 (2013.01);
Abstract
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.